Skip to content
lifestyle.utv.ie
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
FibroBiologics, Inc.
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
May 5, 2026
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
May 5, 2026
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
May 5, 2026
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
May 4, 2026
FibroBiologics Compliant with All Nasdaq Listing Requirements
May 3, 2026
FibroBiologics Announces Closing of $3 Million Public Offering
May 1, 2026
FibroBiologics Announces Pricing of $3 Million Public Offering
May 1, 2026
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
May 1, 2026
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
April 30, 2026
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
April 28, 2026
←
Previous Page
1
2
3
Next Page
→